Treating B-cell Acute Lymphoid Leukemia Using CAR NK Cell Therapy

Abstract

CAR NK cell therapy is now emerging as an attractive, affordable, and effective way to treat cancers. The CAR NK cells can have an enhanced cytotoxicity against malignant cells by a CRISPR-Cas9 mediated knockout of the inhibitory receptor Tim-3 and by using a second-generation sCAR with costimulatory domains and co-stimulatory ligands such as 4-1BB. Using the CAR NK cells in conjunction with monoclonal antibody treatments such as rituximab would also enhance the effectiveness of the CAR NK cells through CDCC (complement dependent cytotoxicity).